Cellectis announced a strategic transformation that affects its entire development posture, shifting away from allogeneic CAR-T into in vivo gene editing. The company cited the momentum of its preclinical proof of concept for its severe dyslipidemia programs (including .HEAL-101 and .HEAL-201) to support the new in vivo focus. In a separate re-positioning within the cell-therapy landscape, Cellectis also moved to “offload” lead CAR-T work and emphasize in vivo approaches—reinforcing that competitive dynamics and technical timelines are driving platform-level reallocation across the donor-derived cell therapy space.